GFM
ACAD icon

GF Fund Management’s Acadia Pharmaceuticals ACAD Stock Holding History

GF Fund Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.3K Sell
3,609
-190
-5% -$4.18K ﹤0.01% 342
2026
Q1 		$84.6K Buy
3,799
+475
+14% +$11.4K ﹤0.01% 356
2025
Q4 		$88.8K Sell
3,324
-306
-8% -$7.31K ﹤0.01% 354
2025
Q3 		$77.5K Sell
3,630
-630
-15% -$14.9K ﹤0.01% 354
2025
Q2 		$91.9K Hold
4,260
– – ﹤0.01% 373
2025
Q1 		$70.8K Buy
4,260
+766
+22% +$13.9K ﹤0.01% 391
2024
Q4 		$64.1K Buy
+3,494
New +$56.4K ﹤0.01% 365

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GF Fund Management's ACAD Position: Q2 2026 in Review

GF Fund Management reduced its Acadia Pharmaceuticals (ACAD) stake by 5% in Q2 2026, selling an estimated $4.18K and leaving 3,609 shares worth $91.3K. The position accounts for ﹤0.01% of the portfolio, ranked #342.

GF Fund Management first reported a position in ACAD in Q4 2024 and has held it in 7 quarters since. The position peaked at $91.9K in Q2 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • GF Fund Management held 3,609 shares of Acadia Pharmaceuticals worth $91.3K as of Q2 2026.
  • GF Fund Management sold 190 Acadia Pharmaceuticals shares in Q2 2026, an estimated $4.18K.
  • Acadia Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #342 holding.
  • GF Fund Management first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Acadia Pharmaceuticals position peaked at $91.9K in Q2 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.